Target intelligence / Profile preview

Mesoderm posterior basic helix-loop-helix transcription factor 1 (MESP1)

Target
MESP1
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) protein
01

Overview

Mesoderm posterior basic helix-loop-helix transcription factor 1 (MESP1) is a master regulatory transcription factor critically involved in early embryonic development, particularly in the specification of cardiovascular progenitors in the mesoderm[1][3]. MESP1 is expressed transiently during gastrulation, marking progenitors that give rise to all major cardiac lineages—including myocardium, endocardium, epicardium, and the cardiac conduction system[3]. It functions at the top of the cardiovascular gene regulatory hierarchy, rapidly inducing other cardiac transcription factors (e.g., Nkx2-5, Gata4, Hand2, Mef2c) and promoting mesoderm differentiation while repressing genes involved in alternative fates such as endoderm or hematopoietic lineages[1][3]. Loss of MESP1 function in mice causes defects in heart formation due to impaired migration and specification of cardiac progenitor cells, although some redundancy exists with the related factor MESP2[3]. MESP1 is not a druggable target in standard therapeutic contexts; rather, its primary importance is in developmental and regenerative biology research, where manipulation of its expression in embryonic stem cells is used to direct cardiogenesis in vitro[1][3][2].

Other names
Mesoderm posterior protein 1BHLHC5bHLHc5MGC10676Class C basic helix-loop-helix protein 5mesoderm posterior 1 homologmesoderm posterior protein 1Mesp1
02

Biological functions

Regulation of cardiovascular progenitor specificationInduction of mesoderm differentiationPromotion of epithelial–mesenchymal transition (EMT)Regulation of cell migrationCardiac, endothelial, and smooth muscle cell lineage specificationRepression of non-cardiac mesoderm and endoderm fates
03

Disease associations

Congenital heart defects (via loss of function in embryogenesis)Other (primarily developmental disorders; no established direct link to adult human diseases like cancer)
04

Safety considerations

Potential developmental defects if dysregulated in embryonic contextTargeting MESP1 for therapy is unproven and not established in the literature

Beyond the preview

Go deeper on Mesoderm posterior basic helix-loop-helix transcription factor 1 (MESP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesoderm posterior basic helix-loop-helix transcription factor 1 (MESP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call